Cialis vs Alprostadil (Caverject/MUSE): Titration Speed and Tolerability Compared

How Each Drug Works and Why It Matters for Titration

Tadalafil and alprostadil treat erectile dysfunction through entirely different mechanisms, and that difference shapes every aspect of their dose-finding process. Tadalafil inhibits phosphodiesterase type 5 (PDE5), which allows cyclic GMP to accumulate and smooth muscle to relax only when nitric oxide (NO) is released during sexual arousal. Alprostadil is a synthetic analogue of prostaglandin E1 (PGE1) that activates adenylyl cyclase directly, raising intracellular cAMP and relaxing corporal smooth muscle independent of NO or sexual stimulation.

Tadalafil: Dependent on an Intact Signaling Chain

Because tadalafil amplifies an existing signal rather than creating one, its dose response is tied to how functional that NO pathway is. Men with severe neurogenic or post-prostatectomy ED often have a blunted NO response, which is why higher doses (20 mg) may still underperform in that population even after full titration. The FDA-approved label for tadalafil for erectile dysfunction (accessdata.fda.gov) lists the starting dose at 10 mg taken before anticipated sexual activity, with adjustment based on response and tolerability.

Alprostadil: A Direct Agonist That Bypasses Neurovascular Deficits

Alprostadil does not depend on libido, arousal, or an intact pudendal nerve to produce an erection. That independence makes it the preferred second-line or third-line agent for men whose vascular or neurological damage is severe enough to make PDE5 inhibition insufficient. It also means the dose-response curve is steeper and more predictable once the right dose is found, but that predictability comes with a trade-off: local administration produces local side effects that oral therapy avoids entirely.

Titration Protocols: Step by Step

Tadalafil On-Demand Titration

The standard on-demand titration sequence for tadalafil runs as follows. A clinician prescribes 10 mg as the starting dose. After two to four attempts at home, the patient reports back. If the response is insufficient and the drug was tolerated, the dose moves to 20 mg. If side effects were bothersome at 10 mg, the dose drops to 5 mg. The entire sequence rarely takes more than two to three weeks for motivated patients. The FDA label permits doses as low as 2.5 mg for daily use, which is a separate titration path used primarily for men who prefer spontaneous intercourse without dosing planning.

Brock et al. (J Urol 2002, N=216) evaluated tadalafil 10 mg and 20 mg against placebo in men with mild-to-moderate ED and found that 20 mg produced successful intercourse on approximately 81% of attempts compared with 35% for placebo (P<0.001) [1]. That large effect size means many men find their effective dose on the first or second try.

Alprostadil Injection (Caverject) Titration

Caverject titration is done in a clinic, not at home. The American Urological Association (AUA) and the prescribing information both specify that the first injection must be administered by a healthcare provider to monitor for hypotension, prolonged erection, or priapism. The protocol is:

• Visit 1: 1.25 mcg intracavernosal injection. Observe for 60 minutes. If no response, increase to 2.5 mcg at the same visit or schedule a second visit.
• Visit 2: Increase by 5 mcg increments for vasculogenic ED or 1.25 mcg increments for neurogenic ED. Identify the lowest dose that produces an erection firm enough for intercourse and lasting no more than 60 minutes.
• Home use: The confirmed dose is prescribed for home self-injection. Maximum dose is 60 mcg per the FDA-approved labeling (accessdata.fda.gov).

This process typically requires one to three clinic visits spread over one to two weeks. The in-office requirement adds time but provides critical safety data that oral titration does not require.

Alprostadil Urethral Suppository (MUSE) Titration

MUSE (Medicated Urethral System for Erection) delivers alprostadil as a small pellet inserted into the urethra via a single-use applicator. Available doses are 125 mcg, 250 mcg, 500 mcg, and 1000 mcg. Per the FDA-approved MUSE labeling (accessdata.fda.gov), the first dose must be administered in a medical office to check for hypotension and syncope. Titration begins at 125 to 250 mcg and steps up by one dose level based on response. Maximum is 1000 mcg, and the drug should not be used more than twice in 24 hours.

Linet et al. (NEJM 1996, N=1511) showed that intracavernosal alprostadil produced erections sufficient for intercourse in 87% of injection attempts at the optimal dose versus 24% with placebo (P<0.001), with urethral alprostadil (MUSE) producing somewhat lower but still clinically meaningful response rates [2]. That same study documented penile pain in 37% of men using the injection, the most commonly reported local adverse event.

Tolerability: Systemic vs. Local Side Effects

The tolerability gap between these two drugs is real and clinically significant. Tadalafil produces systemic side effects because it is swallowed and distributed throughout the body. Alprostadil's side effect profile is dominated by local reactions at the site of administration.

Tadalafil Side Effects

The most common adverse effects of tadalafil reported in prescribing label trials include:

• Headache (11-15%)
• Dyspepsia (4-10%)
• Back pain (3-9%, attributed to PDE11A inhibition in spinal muscles)
• Flushing (2-4%)
• Nasal congestion (1-3%)
• Visual disturbances: rare, but the FDA label carries a warning for non-arteritic anterior ischemic optic neuropathy (NAION)

Systemic hypotension is the safety concern requiring the absolute contraindication with nitrates. Tadalafil's 17.5-hour half-life means that a man who takes a daily 5 mg dose and then receives nitroglycerin in an emergency department is at risk for severe hypotension for up to 48 hours after his last dose. Clinicians managing cardiovascular comorbidities must account for that window.

Alprostadil Side Effects

The tolerability story for alprostadil centers on local discomfort rather than systemic effects:

• Penile pain with injection: 37% of men in Linet et al. [2], which is the most frequently cited reason for discontinuation
• Urethral burning and minor urethral bleeding with MUSE: reported in 10-35% of users depending on the study
• Prolonged erection (>4 hours): 4-5% with intracavernosal injection at doses above 20 mcg
• Priapism (>6 hours): <1% but requires emergency medical treatment
• Penile fibrosis: reported in 2-3% with long-term injection use, lower with proper injection technique
• Hypotension and dizziness: systemic effects are rare but documented with MUSE at higher doses, particularly in men with cardiovascular disease

The needle itself is a barrier for many patients. Published discontinuation rates for Caverject in long-term follow-up studies range from 40% to 60% at one year, with needle aversion cited as a primary factor. MUSE avoids the needle but has lower efficacy, particularly in men with severe vasculogenic ED.

Comparing Discontinuation Rates

Tadalafil has substantially better long-term adherence than either form of alprostadil when used in a PDE5i-responsive population. The non-invasive route of administration, once-daily dosing option, and absence of local pain all support persistence. Alprostadil is prescribed when tadalafil and other PDE5 inhibitors have been tried and found insufficient, so direct head-to-head discontinuation comparisons must account for the more severely impaired baseline population.

Efficacy by ED Etiology

Vasculogenic ED

Vasculogenic ED, caused by arterial insufficiency or venous leakage, responds to both agents but differently. Tadalafil at 20 mg produces consistent erections when residual arterial function remains. Men with more complete vascular compromise may achieve an IIEF-EF domain score increase of only 4 to 6 points, falling short of the minimal clinically important difference of 4 for mild ED and 8 for severe ED per established thresholds [3]. Caverject at doses of 10 to 40 mcg bypasses the arterial contribution partly because PGE1 directly relaxes smooth muscle, producing a more reliable response even in men with moderate arterial disease.

Neurogenic ED (Post-Prostatectomy)

Men with neurogenic ED after radical prostatectomy represent the population where alprostadil most clearly outperforms tadalafil. Because cavernous nerve damage eliminates the NO signal that tadalafil amplifies, even 20 mg tadalafil may produce only modest results in the early post-operative period. Caverject at low neurogenic-titration doses (1.25 to 5 mcg) often produces a more reliable erection in this group. Some centers use both agents sequentially as part of penile rehabilitation protocols, though the evidence base for rehabilitation per se remains debated.

Psychogenic ED

Psychogenic ED, in which the NO pathway is intact but anxiety or relationship factors inhibit arousal, tends to respond well to tadalafil. The drug's long duration of action (up to 36 hours) reduces performance pressure. Alprostadil is rarely first-choice for psychogenic ED because the injection or suppository itself can exacerbate performance anxiety, and the erection it produces is not dependent on arousal, which can feel unnatural to some patients.

Drug Interactions and Contraindications

Tadalafil Interactions

Tadalafil carries a class-wide PDE5 inhibitor contraindication with all forms of organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite). Co-administration may cause a drop in systolic blood pressure of 25 to 57 mmHg. Alpha-blockers such as doxazosin require caution; the FDA label recommends starting tadalafil at 5 mg in men already on alpha-blockers. Strong CYP3A4 inhibitors (ketoconazole, ritonavir) raise tadalafil plasma levels significantly and require dose reduction to 10 mg maximum.

Alprostadil Interactions

Alprostadil has no nitrate interaction and no significant CYP3A4 interactions, making it usable in men taking nitrates for cardiovascular disease. This is one of its practical advantages over all PDE5 inhibitors. However, anticoagulants (warfarin, direct oral anticoagulants) increase bruising and hematoma risk at injection sites. Men taking vasoactive agents for blood pressure management should be monitored for additive hypotension, particularly with MUSE.

Switching From Tadalafil to Alprostadil: Who Qualifies and How

Criteria for Switching

Switching from tadalafil to alprostadil is appropriate when:

1. The patient has tried tadalafil 20 mg on at least four separate occasions with adequate sexual stimulation and found the response insufficient.
2. A trial of daily tadalafil 5 mg for at least four weeks has also failed.
3. Contraindications to PDE5 inhibition exist (e.g., concurrent nitrate therapy required for angina management).
4. A post-prostatectomy patient is more than six months post-surgery and has not recovered sufficient cavernous nerve function to respond to oral therapy.

The Princeton III Consensus Panel recommends that men failing two different PDE5 inhibitors at maximum doses be offered second-line therapy, which includes intracavernosal alprostadil, prior to discussing prosthetic surgery [4].

The Switching Process

When a patient transitions from tadalafil to Caverject, the clinical steps are practical and straightforward. Tadalafil is stopped. There is no wash-out period required before beginning alprostadil titration because alprostadil does not interact with residual tadalafil. The first Caverject dose is administered in office per the titration protocol described above. Injection technique training adds approximately 20 to 30 minutes to the initial clinic visit and is critical for minimizing fibrosis risk.

For men reluctant to use injection therapy, a trial of MUSE is a reasonable intermediate step before committing to intracavernosal injection. MUSE is less effective in severe vasculogenic ED, but its non-needle delivery may improve acceptance and quality-of-life scores, particularly in men over 65.

Combination Therapy

Some urologists prescribe low-dose Caverject in combination with continued low-dose tadalafil (5 mg daily) as a bridge strategy in men who have partial responses to each agent alone. The combination has been described in small case series and is not FDA-approved as a combination regimen. Clinicians attempting this approach should monitor for additive hypotension and counsel patients on priapism risk.

Practical Patient Decision Guide

The choice between tadalafil and alprostadil should be individualized. The following framework reflects standard clinical reasoning rather than a rigid algorithm.

Start with tadalafil if:

• The patient has mild-to-moderate ED with intact vascular and neurological function
• No concurrent nitrate therapy is needed
• The patient prefers non-invasive, spontaneous-seeming treatment
• Psychogenic contributors are significant

Move to alprostadil if:

• Tadalafil 20 mg on-demand and 5 mg daily have both failed after adequate trials
• Concurrent nitrate use makes PDE5 inhibition unsafe
• Post-prostatectomy neurogenic ED is the primary etiology
• The patient accepts injection or urethral administration after counseling

Consider Caverject over MUSE if:

• Severe vasculogenic ED is the etiology (MUSE response rates are lower in this group)
• The patient has already tried MUSE without adequate response

Consider MUSE over Caverject if:

• Needle phobia is significant
• The patient has adequate vascular reserve (mild-to-moderate vasculogenic or psychogenic ED)
• Anticoagulation makes injection bruising a concern

Monitoring During Titration

Tadalafil Monitoring

No laboratory monitoring is required during tadalafil titration for most patients. Blood pressure should be assessed at baseline if cardiovascular risk is present. Men on alpha-blockers should have blood pressure checked after starting tadalafil. The prescribing clinician should ask about visual changes, sudden hearing loss, and chest pain at follow-up visits given the rare but serious adverse events listed in the FDA label.

Alprostadil Monitoring

The first dose of Caverject or MUSE must be given in a monitored clinical setting per FDA labeling. After each in-office titration dose, blood pressure and pulse are measured at 30 and 60 minutes post-administration. Erection duration is documented. Home use does not require vital sign monitoring, but patients must be counseled that an erection lasting more than four hours requires immediate emergency care. A 30-day and 90-day telephone or in-person follow-up is appropriate to assess for penile nodules, pain, or injection-site bruising that could indicate early fibrosis.